Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13535037 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1OPRM1OPRL1 | |
| SCHEMBL13221741 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1OPRM1OPRL1 | |
| SCHEMBL12443598 | 0.81 | NEK2 (0.36) | — | |
| SCHEMBL6616185 | 0.79 | PDE4A (0.32) | ALDH1A1 | |
| SCHEMBL1943173 | 0.79 | L3MBTL1 (0.43) | ALDH1A1 | |
| SCHEMBL14163627 | 0.79 | — | — | |
| SCHEMBL14158141 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL4200428 | 0.78 | PDE4A (0.31) | ALDH1A1 | |
| SCHEMBL10203450 | 0.78 | LPAR1 (0.31) | ALDH1A1 | |
| SCHEMBL10203457 | 0.78 | LPAR1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | TRIM24 4829/4885TRIM33 4779/4885ALDH1A1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.